10-Q quarterly report · filed Nov 10, 2026

Anteris Technologies Global Corp. (AVR) Q3 2026 10-Q Quarterly Report

Short answer

Anteris Technologies Global Corp. (AVR) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $519,000 (up 21.0% year over year) with net income of −$27M.

Q3 2026 key financials · XBRL

Revenue
$519,000
+21.0% YoY · −48.6% QoQ
Net income
−$27M
−20.6% YoY · +7.8% QoQ
Operating margin
-5749.7%
EPS (diluted)
−$0.27
+56.5% YoY · +10.0% QoQ

Source: XBRL data from the Anteris Technologies Global Corp. (AVR) Q3 2026 10-Q on SEC EDGAR. USD.

Anteris Technologies Global Corp. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $519K, up 21% YoY from $429K, driven by higher 4C tissue-product sales
  • Gross margin percentage not disclosed, described as generally consistent YoY
  • Operating loss $29.8M vs $22.3M YoY, operating margin -5,749% vs -5,189%
  • Cash, equivalents and restricted cash $236.3M; operating cash outflow $72.4M for nine months
  • Financing provided $298.4M, including $308.6M net stock proceeds; ongoing losses and additional funding needs expected

Risk Factors

  • Regulatory risk: PARADIGM Trial approval under FDA IDE could be revoked
  • Clinical risk: PARADIGM Trial may be unsuccessful despite FDA authorization
  • Approval risk: DurAVR THV System may not receive FDA PMA
  • Compliance risk: FDA may impose costly post-market testing or controls after PMA
  • Revenue risk: approval delays could prevent revenue generation or profitability

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Anteris Technologies Global Corp. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.